Abstract: An actuator can include an outer body. At least a portion of the outer body can be configured to pivot. The actuator can include a contracting member, such as a shape memory material member. When an activation input is provided to the contracting member, the contracting member can contract. As a result, the actuator can be caused to morph into an activated configuration in which a dimension, such as the height, of the actuator increases.

Abstract: The invention relates to a method of improved ammunition production, particularly to a metal matrix composite(MMC) end cap, suitable for forming a cartridge case, said end cap comprising an admixture of a metal powder, a binder matrix material, wherein said admixture has been caused to solidify in the shape of said end cap.

Abstract: The invention relates to a method of improved ammunition production, more specifically to a cellular structure end cap, suitable for an ammunition round, said end cap comprising a porous 3D spatial structure in the shape of said end cap, wherein in said porous 3D spatial structure comprises a surface skin.

Abstract: A lightweight end cap for an ammunition cartridge, said end cap having a central axis along its axial length, with a first radius; wherein said end cap further comprises a swept volume rebate; having a second radius less than the first radius, wherein the second radius is at least 10% smaller than the first radius, and wherein the swept volume rebate extends along at least 10% of the axial length of said end cap, wherein the end cap further comprises an extractor groove suitable for receiving an ejection mechanism.

Abstract: There is provided an ammunition belt link comprising, a sprung wire, said sprung wire arranged to form a first receiving portion suitable for retaining a first ammunition cartridge, a second receiving portion suitable for retaining a second ammunition cartridge, a spacer between said first receiving and second receiving portions; and an ammunition cartridge locator aide, said aide locates in an ejector groove of a received cartridge.

Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

Abstract: Provided herein are methods, assays and devices for the detection and diagnosis of autoimmune diseases, including systemic lupus erythematosus. The methods, assays and devices provided herein analyzes binding patterns of peripheral-blood antibodies on peptide array that correlates well with current systemic lupus erythematosus clinical assessment standards.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract: There is provided an ammunition belt link comprising, a sprung wire, said sprung wire arranged to form a first receiving portion suitable for retaining a first ammunition cartridge, a second receiving portion suitable for retaining a second ammunition cartridge, a spacer between said first receiving and second receiving portions; and an ammunition cartridge locator aide, said aide locates in an ejector groove of a received cartridge.

Abstract: According to the present invention, there is provided an ammunition belt link comprising, a sprung wire, said sprung wire arranged to form a first receiving portion suitable for retaining a first ammunition cartridge, a second receiving portion suitable for retaining a second ammunition cartridge, a spacer between said first receiving and second receiving portions, an ammunition cartridge locator aide, said locator aid locates in an ejector groove of a received cartridge and, the wire ammunition belt link further comprising a support surface suitable for retaining the first and/or second ammunition cartridge.

Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Abstract: Microfluidic devices and methods of quantifying fatty acids and/or specialized pro-resolving mediators and/or fatty acid metabolites present in a fluid sample on a microfluidic device are described herein. The methods include extracting fatty acid esters containing fatty acids from the fluid sample, combining the extracted fatty acid esters with a hydrolyzing agent to cleave the fatty acids from the extracted fatty acid esters and form free fatty acids, and quantifying the free fatty acids by performing a bioassay specific to the free fatty acids. Microfluidic devices and methods of quantifying fatty acid metabolites present in a fluid sample on a microfluidic device are also described herein.

Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Abstract: Fault injection testing for field programmable gate array (FPGA) devices including: interfacing with a FPGA device under test (DUT); imaging a configuration RAM (CRAM) of the FPGA DUT with a first configuration image to define a first operational function of the FPGA DUT where the CRAM includes a plurality of CRAM bits, injecting a plurality of single event upsets into a portion of the plurality of the CRAM bits while the FPGA DUT is operating; concurrently monitoring operations of the FPGA DUT and a reference FPGA device; comparing outputs of the FPGA DUT with outputs of the reference FPGA device during concurrent operations, and if there is a mismatch between the outputs of the FPGA DUT and the reference FPGA, determining that error events have occurred within the FPGA DUT; and storing the error events and CRAM location data associated with corresponding single event upsets in an error log.

Abstract: Fault injection testing for field programmable gate array (FPGA) devices including: interfacing with a FPGA device under test (DUT); imaging a configuration RAM (CRAM) of the FPGA DUT with a first configuration image to define a first operational function of the FPGA DUT where the CRAM includes a plurality of CRAM bits, injecting a plurality of single event upsets into a portion of the plurality of the CRAM bits while the FPGA DUT is operating; concurrently monitoring operations of the FPGA DUT and a reference FPGA device; comparing outputs of the FPGA DUT with outputs of the reference FPGA device during concurrent operations, and if there is a mismatch between the outputs of the FPGA DUT and the reference FPGA, determining that error events have occurred within the FPGA DUT; and storing the error events and CRAM location data associated with corresponding single event upsets in an error log.

Abstract: The disclosed embodiments concern methods, devices, and systems for identifying candidate biomarkers useful for the diagnosis, prognosis, monitoring and screening and/or as targets for the treatment of diseases and conditions in subjects, in particular autoimmune and infectious diseases. The identification of candidate biomarkers is predicated on identifying discriminating peptides present on a peptide array, which can distinguish samples from different subjects having different health conditions by the binding patterns of antibodies present in the samples.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-diethylethyl)-5-hydroxyphenyl]-1,4-dihydro-1-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-diethylethyl)-5-hydroxyphenyl]-1,4-dihydro-1-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.